Exhibit 99.1 Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates • HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 • Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million • Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles program • Conference call today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, CA – May 8, 2024 – Dynavax Tec ...